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Neuroendocrine tumors can originate almost everywhere in the body and consist of a great 
variety of subtypes. This paper focuses on molecular imaging methods using nuclear 
medicine techniques in neuroendocrine tumors, coupling molecular uptake mechanisms of 
radiotracers with clinical results. A non-systematic review is presented on receptor based 
and metabolic imaging methods. Receptor-based imaging covers the molecular 
backgrounds of somatostatin, vaso-intestinal peptide (VIP), bombesin and cholecystokinin 
(CCK) receptors and their link with nuclear imaging. Imaging methods based on specific 
metabolic properties include metaiodobenzylguanidine (MIBG) and dimercaptosuccinic 
acid (DMSA-V) scintigraphy as well as more modern positron emission tomography (PET) 
based methods using radiolabeled analogues of amino acids, glucose, 
dihydroxyphenylalanine (DOPA), dopamine and tryptophan. Diagnostic sensitivities are 
presented for each imaging method and for each neuroendocrine tumor subtype. Finally, a 
Forest plot analysis of diagnostic performance is presented for each tumor type in order to 
provide a comprehensive overview for clinical use. 
 
Introduction 
Neuroendocrine tumors are unique and rare tumors originating from neuroendocrine cells. 
These neuroendocrine cells are postulated to arise from common precursor cells of the 
embryologic neural crest and are dispersed throughout the human body. Characteristic is a 
common phenotype consisting of the simultaneous expression of general protein markers of 
neuroendocrine cells and hormonal products specific to each cell type1. The main function 
of neuroendocrine cells is to regulate a large variety of body functions through paracrine 
action with dedicated amines and peptides, of which the “biogenic amines”, such as 
serotonin and catecholamines, are most prominent. In order to be able to synthesize these 
amines, neuroendocrine cells have the ability to take-up and decarboxylate amine 
precursors (APUD; amine precursor uptake and decarboxylation). Other biogenic amines, 
substances such as adrenocorticotrophic hormone, growth hormone, neuropeptide K, 
substance P, bradykinin, kallikrein and prostaglandins can also be secreted2,3. 
Neuroendocrine tumors arise in nearly every organ but primary sites in gastrointestinal 
(56%) and bronchopulmonary (12%) tracts are most frequent4. 
Due to the slow growth of most neuroendocrine tumors and the long time span between the 
onset of symptoms, many patients present with metastases (figure 1). Even with advanced 
disease, patients may survive for many years. However, there are also subtypes, which 
behave more aggressively. The diagnosis is based on histology and can be considered when 
specific symptoms induced by tumor products are present, such as diarrhea or flushing. 
Apart from clinical symptoms, determination of tumor secretory products using 
biochemical assays can assist in obtaining a diagnosis. 
A division based on the embryological origin of the organs in which neuroendocrine tumors 
arise has been made in the past. This division classifies these tumors as foregut, midgut and 
hindgut tumors. However, the recent World Health Organization (WHO) classification of 
the different subtypes of neuroendocrine tumors of gastro-intestinal and pancreatic origin is 
based on histopathologic characteristics consisting of cellular grading, primary tumor size, 
primary tumor localization, proliferation markers, degree of invasiveness and the 
production of biologically active substances. The main categories defined by this 
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classification are the well differentiated endocrine tumors with a low grade of malignancy, 
well differentiated, more aggressive carcinomas, poorly differentiated endocrine 
carcinomas with a high grade of malignancy and a poor prognosis and finally mixed 
exocrine–endocrine tumors. In this WHO classification the term carcinoid is abandoned and 
replaced by neuroendocrine tumor5. 
Currently, there is a broad variety of treatment options for patients with neuroendocrine 
tumors. Surgery is the only curative option. When cure is not possible, palliative treatment 
aims to control symptoms, maintain local tumor control and prolong life. Palliative 
procedures include surgical debulking, correction of bowel obstruction, chemo-
embolizations, or systemic treatment using interferon-α or somatostatin analogues2. Other 
treatment options are chemotherapy and radionuclide therapy. New targeted therapies such 




Figure 1. Full-color in appendix. Metastasized carcinoid. 18F-DOPA PET scan (A), Octreotide scan (B) and 18F-DOPA PET-CT 
fusion image (C) of a female patient presenting with a metastasized carcinoid. This patient illustrates the intra-individual 
heterogeneity in the uptake of different tracers by tumor metastases. 
 
Accurate localization of tumor lesions can guide treatment decisions. In general, 
radiological techniques such as CT, ultrasound or MRI are applied in staging and restaging, 
but also nuclear medicine techniques, such as somatostatin receptor scintigraphy (SRS), 
have proven to be of great value. The presence of somatostatin receptors on many 
neuroendocrine tumors was the driving force that enabled the development of SRS. Besides 
receptors, the remarkable metabolic activity of specific biochemical pathways used in 
substance synthesis provides possibilities for molecular nuclear medicine imaging. 
The unique characteristics of neuroendocrine tumors have led to the development of 
interesting new diagnostic methods for these tumors over the last years, both in receptor 
imaging and metabolic imaging. Especially the increase in positron emission tomography 
(PET) facilities allows developments of tracers for new molecular targets with a high-
resolution method for imaging. In addition new insights in the genetic, biochemical and 
metabolic aspects of subtypes of the neuroendocrine tumor family have arisen over the last 
years. It is therefore important to understand the receptor and metabolic targets for 
neuroendocrine tumors, as the molecular mechanisms that drive tracer uptake, translate into 
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images and determine the final clinical applicability. 
The unique characteristics of neuroendocrine tumors are increasingly exploited to 
successfully enhance our imaging and therapeutical options for these tumors. Three 
directions can be seen in the development of new tracers for imaging use. The first uses 
tumor receptor expression, the second uses the metabolic properties and the last method 
uses antibodies. 
Therefore, the purpose of this review is to describe the receptor and metabolic imaging 
methods of neuroendocrine tumors and translate the molecular uptake mechanisms into 
clinical parameters such as sensitivity and specificity. For this purpose, a review of current 
literature is presented, both for imaging methods and for tumor types. 
 
Search strategy and selection criteria 
For this non-systematic review, a Medline and PubMed search was performed. Due to the 
many subtypes of neuroendocrine tumor and imaging methods a multitude of different 
search terms was necessary. A detailed list is available on request. Only papers with an 
English abstract published over the last 10 years (1995) were included. Material from 
review articles also referring to older studies was evaluated and was used if relevant. 
Reference lists of individual papers were also analyzed for study selection. Only studies 
from which a clear description of sensitivity or specificity for individual tumor subgroups 
could be derived were included. Data from all sources were sorted and divided over 
subcategories of tracer and tumor type. In general, studies with fewer than 10 subjects were 
excluded, however, due to the rarity of a number of tumor types, some of these reports or 
small studies were included. The number of patients included in the studies was used as a 
weight factor in summarizing results for different tracers and is represented by a square in 
the Forest plot analysis. The size of the square represents the weight that the studies exert in 
the analysis. Sensitivity values given in the figures denote a lesion-based sensitivity for the 
detection of all types of tumor deposits. 
 
Nuclear imaging methods 
The methods for nuclear imaging of neuroendocrine tumors can be divided in three main 
categories, namely tracers based on a) the selective expression of different receptors, b) 
metabolic properties of tumors and c) tracers which exploit antigens expressed by the 
tumors. For each category, currently available tracers will be described and their clinical 
impact. A schematic overview of the uptake mechanisms of these tracers can be found in 
figure 2. 
A general principle in nuclear medicine is that detectability of lesions primarily depends on 
the amount of tracer localized in a lesion, and only indirectly on the size of that lesion. In 
theory a 1 mm lesion can be detected as long as there is enough tracer uptake. On the 
images, such a lesion will result in a ‘hot-spot’ with larger dimensions and vague borders. 
This is especially true for imaging with gamma cameras, such as SPECT, which have a 
considerable lower spatial resolution than methods based on PET. A prerequisite for 
molecular uptake mechanisms therefore is that the magnitude of tracer uptake is high and 
the background uptake low. In daily practice of commonly used tracer methods, these 
principles translate into a detection limit of 1-2 cm for conventional gamma camera 
imaging and 0.5-1 cm for PET imaging. 
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Figure 2. Full-color in appendix. Metabolic pathways. In this figure the different metabolic pathways by which neuroendocrine 
tumors can be visualized using nuclear medicine imaging techniques are schematically depicted. Three major routes can be 
identified: receptor based techniques, techniques which use the metabolic properties of these tumors and labeled antibody based 
techniques.  
 
Receptor based imaging methods 
Somatostatin receptor imaging 
Currently somatostatin receptor imaging is the method of choice for the staging of 
neuroendocrine tumors8. Somatostatin is a small regulatory peptide, which is widely 
distributed in the human body. Besides its function as a neurotransmitter in the 
hypothalamus, it has an inhibitory effect on the production of several exocrine hormones in 
the gastrointestinal tract and anti-proliferative effects9. Somatostatin receptors are G protein 
coupled receptors on the cell membrane which recognize the ligand and generate a trans-
membrane signal. The resulting hormone-receptor complexes have the ability to be 
internalized. Once internalized, these vesicles fuse with lysosomes, resulting in hormone 
degradation or receptor recycling10. Thus far, 6 different somatostatin receptors have been 
cloned, namely sst1-sst5 (sst2 can be alternately spliced to yield two products, sst2A and 
sst2B). 
Neuroendocrine tumors frequently express a high density of somatostatin receptors, which 
is exploited by imaging techniques using somatostatin analogues. These analogues have 
been developed because somatostatin itself has a very short plasma half life (~ 3 min). For 
most somatostatin analogues internalization of the 111In-octreotide complex with 
residualization of the 111In label is the most likely mechanism accounting for the good 
scintigraphic tumor to background ratio observed 24 h after injection11. Currently radio-
labeled analogues of somatostatin such as octreotide, vapreotide and MK678, are in clinical 
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varying affinity to the sst3 and sst4 receptors. When chelators such as DTPA or DOTA are 
coupled to somatostatin analogues, these molecules can thereafter be labeled with for 
instance 111In or 99mTc for scintigraphic purposes. When labeled with positron emitting 
isotopes, such as 18F, 64Cu or 68Ga the somatostatin analogues can be used for PET 
imaging12,13. There are many new developments in newer better chelators (i.e. DOTA, 
EDDA or HYNIC) and analogues with more rapid internalization properties14. 
Based on the high receptor expression, somatostatin receptor imaging using 111In-octreotide 
provides important information on tumor localizations of many neuroendocrine tumors. 
SRS is now widely available, and yields the best results in paragangliomas and 
neuroendocrine gastrointestinal tumors (87 and 88% sensitivity). SRS is least suitable for 
medullary thyroid carcinoma (44% sensitivity). In general the SRS whole body scan 
information is complementary to the more focal information given by CT or MRI. In figure 
3 literature results are summarized in a Forest plot. 
The three imaging methods described below, namely VIP, bombesin and CCK receptor 
imaging are still experimental and are not yet available for routine clinical use. In figure 4 
results for VIP, CCK and antibody imaging are presented. 
 
Vasoactive intestinal peptide receptor imaging (VIP) 
VIP and pituitary adenylate cyclase activating peptide (PACAP), both member of the 
secretin like peptides, are neuropeptides which regulate a broad spectrum of biological 
activities, including vasodilatation, stimulation of secretion of various hormones, 
immunomodulation and promotion of cell proliferation. There are two groups of receptors, 
namely VPAC1 and VPAC2, which are receptors with high affinity for VIP, PACAP and 
PAC1, which is characterized, by a high affinity for PACAP but a low affinity for VIP. 
These receptors function through two distinct G-protein-coupled receptor subtypes that can 
also be internalized15. VPAC1 is expressed in most epithelial tissues and the brain, while 
VPAC2 is only present in smooth muscle. Subsequently, these receptors are expressed in 
tumors derived from these tissues. The PAC1 receptor is the only VIP/PACAP receptor 
found on catecholamine producing tumor cells of neuroendocrine origin and 
neuroblastomas. Interestingly VIP/PACAP receptors are absent in medullary thyroid 
cancers16. Proteolytic degradation of VIP in vivo as well as high VPAC1 receptor 
expression in normal epithelial tissues and VPAC2 expression in smooth muscle hampers 
the applicability of this target for neuroendocrine tumor imaging. Recently a 64Cu labeled 
VIP analogue has been developed, which is more stable and has been shown to have a 
higher tumor uptake then the 99mTc labeled VIP analogue. Therefore this analogue might 
become of interest to study over expression of VIP receptors17. Clinical application is 
however still limited. 
 
Bombesin receptor imaging 
Bombesin and gastrin releasing peptides (GRP) are members of the brain-gut peptides 
present in the nervous system, gastrointestinal tract and the pulmonary tract18. GRP 
regulates several physiologic processes in the central and enteric nerve systems. An 
autocrine feedback mechanism involving the expression of bombesin, GRP receptors and 
the production of peptides in tumor cells (i.e. small cell lung cancer or neuroblastoma), can 
stimulate growth of neighboring tumor cells16. 
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Figure 3. Forest plot analysis of SRS imaging per tumor type. Results of SRS imaging sorted per tumor type in a Forest plot 
analysis. On the left side of this plot the tumor type is given with the tracers used in the presented studies. On the right side 
sensitivities from literature data are given with their calculated confidence interval. The size of the solid black square represents the 
weight the corresponding study exerts in this analysis and is calculated using the number of patients included (Mantel-Haenszel 
weight). 
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Figure 4. Forest plot analysis of VIP, CCK and anti-body imaging per tumor type. Results of VIP, CCK and anti-body imaging 
sorted per tumor type in a Forest plot analysis. On the left side of this plot the tumor type is given with the tracers used in the 
presented studies. On the right side sensitivities from literature data are given with their calculated confidence interval. The size of 
the solid black square represents the weight the corresponding study exerts in this analysis and is calculated using the number of 
patients included (Mantel-Haenszel weight). 
 
The bombesin receptor family consists of four receptor subtypes; gastrin releasing peptide 
receptor (BB2), neuromedin B receptors (BB1 or NMB), and bombesin receptors BB3 and 
BB4. GRP receptor proteins are over expressed in tumors such as prostate, breast, renal cell 
and small cell lung cancer. The bombesin and GRP receptors are G protein coupled and can 
internalize after a receptor-agonist complex has been formed. In neuroendocrine tumors 
GRP receptors are preferentially expressed by gastrinomas. Ileal carcinoids express NMB 
receptors whereas small cell lung carcinomas and bronchial carcinoids express the BB3 
receptors19. Bombesin analogues for the GRP receptor have been successfully labeled and 
seem to be interesting candidates for tumor imaging, especially in prostate cancer imaging 
to possibly improve lymph node staging and recurrence detection20. 
 
CCK receptor imaging 
Cholecystokinin and gastrin, both members of the cholecystokinin peptide family, play an 
important role in the neurotransmission in the central nervous system as well as in the 
gastrointestinal physiology. In the gastrointestinal tract they play a role as a growth factor 
for physiologic processes, but also for several neoplasms, i.e. colon and brain tumors16. 
Three G protein-coupled CCK receptors have been identified, namely CCK1, CCK2 and 
CCKC. These CCK receptors have the same internalization mechanisms as somatostatin 
receptors. This internalization is limited to receptor ligands with agonistic activity21. CCK1 
receptors have been detected in i.e. meningioma and neuroblastoma. The CCK2 receptor 
was identified in medullary thyroid carcinoma, astrocytomas, and some neuroendocrine 
gastroenteropancreatic tumors (especially insulinomas) and several soft tissue tumors. In 
pheochromocytomas and paragangliomas CCK2 receptors are rarely expressed. This CCK2 
receptor can be targeted by radiolabeled CCK octapeptides21. The last family member, the 
CCKC receptor, seems to be mainly involved in gastrin mediated proliferation in tumors of 
the nervous system. 
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Only a few clinical studies with CCK imaging have been published. CCK-2 imaging is 
feasible with 111In-DTPA-D-GLU1-minigastrin in patients with metastatic medullary 
thyroid cancer. In 32 patients, the sensitivity for this tracer was 91%22. 
 
Metabolic imaging 
The production of different peptides distinguishes neuroendocrine tumors of other 
malignancies. Therefore the metabolic pathways by which neuroendocrine tumors 
synthesize these peptides and the intracellular processes which are essential to be able to 
sustain production of these peptides are ideal candidates for the development of tracers 
specific for neuroendocrine tumors. These pathways can be targeted at different levels. 
Tracers can be developed as a marker for the transporter proteins, which are necessary to 
supply the substrate into the cell (or intracellular vesicle), as a true substrate for the 
involved pathway, as a substrate which irreversibly binds to an enzyme involved in the 
pathway or as a marker for (re-)uptake of the end product.  
The thus far targeted metabolic pathways and the large amino acid transporter system 
(LAT, which is responsible for the uptake of precursors for both the serotonin and 
catecholamine pathway) will be described below in order of clinical importance. In figure 5 
literature results of metabolic imaging methods for PET are presented. 
 
 
Figure 5. Forest plot analysis of metabolic PET tracer imaging per tumor type. Results of 18F-FDG PET, 18F-DOPA PET, 18F-
Dopamine PET and 11C-5-HTP PET sorted per tumor type in a Forest plot analysis. On the left side of this plot the tumor type is 
given with the tracers used in the presented studies. On the right side sensitivities from literature data are given with their 
calculated confidence interval. The size of the solid black square represents the weight the corresponding study exerts in this 
analysis and is calculated using the number of patients included (Mantel-Haenszel weight). 
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In the catecholamine pathway phenylalanine and intermediate products such as L-3,4 -
L-DOPA) are taken up via the LAT system into the cytoplasm of 
F-DOPA is an F labeled variant of L-DOPA used for PET imaging (figure 6). Although 
 18F atom in 18F -DOPA influences the metabolism, it has no or little 
g. In the proximal tubuli of the kidney 18F-DOPA is rapidly 
dihydroxyphenylalanine (
the cell23. Here these precursors can be metabolized to dopamine, which is transported into 
secretory vesicles via the vesicular monoamine transporter (VMAT) system24. In these 
vesicles dopamine can be further metabolized to noradrenalin and adrenalin. The secretory 
vesicles are responsible for the secretion of end products. Finally, these end products can be 
transported back via i.e. dopamine and noradrenalin transporters. Tracers developed for this 
pathway are the precursor 6-18F-L-3,4-dihydroxyphenylalanine (18F-DOPA), the end 
product 6-18F-dopamine and Metaiodobenzylguanidine (MIBG), which is a substrate for the 
noradrenalin transporter. 
 
- 18F-DOPA PET - 
1818
the presence of the
effect for the transport into the intracellular environment via the cell membrane bound 
LAT2 transporter25. 18F -DOPA is decarboxylated to 18F-dopamine via the enzyme aromatic 
acid decarboxylase (AADC) at a faster rate then L-DOPA. The thus formed dopamine is 
then probably transported into secretory vesicles by VMAT transporters. Although the 
precise uptake mechanism is not fully understood, it appears that the high 18F-DOPA 
uptake in neuroendocrine tumors is the result of increased LAT2 transporter activity to 
satisfy a high precursor turnover due to an increased catecholamine pathway or at least 
increased AADC activity26. 
Somewhat paradoxically, the AADC inhibitor carbidopa is sometimes used in conjunction 
with 18F-DOPA PET imagin
converted by AADC to 18F-dopamine, which is then excreted. This leads to rapid loss of 





Figure 6. Patient with metastatic pancreatic islet cell tumor. 18F-DOPA PET (left) and 11C-5-HTP PET (right) in a patient with 
etastatic pancreatic islet cell tumor. m
 16
Molecular imaging in neuroendocrine tumors: molecular uptake mechanisms and  
clinical results 
The use of oral carbidopa as pre-treatment for 18F-DOPA PET studies improves image 
quality by reducing the conversion of 18F-DOPA and the excretion of 18F-dopamine in the 
kidney in urine. The use of carbidopa also lowers physiological 18F-DOPA uptake in the 
pancreas. The combined effect is a higher availability of 18F-DOPA for tumor uptake27. 
Only a few studies with 18F-DOPA PET in neuroendocrine tumors have thus far been 
published. 18F-DOPA PET yields a very high sensitivity in the detection of carcinoid 
tumors, paragangliomas and pheochromocytomas. For example, in the detection of 
gastrointestinal neuroendocrine tumors, the average sensitivity of 18F-DOPA PET is very 
high (89%, figure 5), whereas in these studies the currently used standard methods (CT and 
SRS imaging) performed not nearly as good (sensitivities of 56% for CT versus 47% for 
SRS imaging)28,29,30. When comparing the thus far published results, 18F-DOPA PET 
enabled best localization of primary tumors and lymph node staging28,29,30. 
There is a very small risk that the use of a catecholamine precursor in patients with a 
carcinoid syndrome can lead to the development of a carcinoid crisis. Only one case has 
thus far been published. This complication can be prevented by a slow tracer injection and 
if necessary an intravenous injection of octreotide31. 
 
- 123I and 131I- Metaiodobenzylguanidine (MIBG) - 
The precise uptake and retention mechanism in neuroendocrine tumors for MIBG has not 
been clarified, but the noradrenalin transporter seems to play an important role for MIBG 
uptake (figure 3). Reports indicate that MIBG acts as an intracellular substrate for the 
vesicular monoamine transporters VMAT1 and VMAT232. These transporters are located on 
the membrane of secretory vesicles of neuroendocrine cells. It seems likely that, once 
MIBG has passed the cell membrane, the VMAT transporters transport MIBG into 
secretory chromaffin granules32. MIBG can be labeled with 123I and 131I. 123I labeled MIBG 
yields the best image quality, due to the superior physical qualities for imaging. It has high 
photon energy of 159 KeV, a half life of 13 hours and it can be administered in a higher 









MIBG scintigraphy has become the imaging method of choice for neuroblastoma and 
pheochromocytomas (for an example see figure 7). MIBG scintigraphy has a lower 
sensitivity for the detection of other neuroendocrine tumors, such as carcinoid (averaging 
50%) (figure 8). Its specificity in detecting pheochromocytoma and neuroblastoma is 
 
Figure 8. Forest plot analysis of MIBG imaging per tumor type. Results of MIBG imaging sorted per tumor type in a Forest plot 
analysis. On the left side of this plot the tumor type is given with the tracers used in the presented studies. On the right side 
sensitivities from literature data are given with their calculated confidence interval. The size of the solid black square represents the 
weight the corresponding study exerts in this analysis and is calculated using the number of patients included (Mantel-Haenszel 
weight). 
 
- 6-18F-Dopamine PET - 
6-18F-Dopamine is a substrate for the monoamine transporters DAT (dopamine transporter) 
and the norepinephrine transporter. After this trans-membrane transport, 18F-dopamine is 
stored in cytoplasmatic secretory vesicles through the VMAT system. However, 18F-
dopamine plasma levels decline rapidly after injection due to me bolization35. 
18
ith a sympathetic innervation. 
superior to other imaging modalities. There is however no explanation for the variation in 
uptake of MIBG by the different neuroendocrine tumors (figure 4). Most studies report 
specificities for MIBG ranging from 80-100% for the detection of pheochromocytoma, but 
less then 80% for the detection its malignant variant. Specificity for neuroblastomas is 84%. 
But, since other neuroendocrine tumors in childhood are rare, a positive MIBG scan is 
nearly diagnostic for a neuroblastoma34. 
 
ta
The PET tracer 6- F-dopamine was developed to visualize sympathiconeuronal 
innervation. This tracer is actively taken up, stored and metabolized by cells from organs 
w
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Organs which have a high 18F-dopamine uptake are the heart, liver, spleen, salivary glands 
and chest wall. 18F-dopamine does not cross the blood-brain barrier, and therefore virtually 
no uptake is seen in the brain. 
18F-dopamine PET is a useful imaging method for the detection of pheochromocytomas36. 
These tumors have a high expression of monoamine transporters, which makes these 
tumors ideal candidates for 18F-dopamine imaging. Due to a low specific activity and the 
pharmacological activity of both labeled and unlabelled dopamine, the maximum injectable 
dose of 18F-dopamine is limited. 
 
Serotonin pathway 
The serotonin and catecholamine pathway have many common features. Precursors for the 
serotonin pathway (tryptophan and 5-hydroxytryptophan, 5-HTP) are taken up via the same 
LAT transport system as utilized by the catecholamine pathway. The conversion from 5-
HTP to serotonin is performed by the same enzyme, which decarboxylizes L-DOPA to 
dopamine, namely the AADC enzyme. The end product, serotonin, is also transported via 
the same VMAT transporter system into secretory vesicles. 
 
- 11C-5-Hydroxytryptophan (11C-5-HTP) PET - 
Thus far, 11C-5-HTP PET is the only tracer for this pathway, which has reached clinical 
application (figure 6). In neuroendocrine tumors, the high uptake via the over expressed 
system L transporter, the rapid decarboxylation by AADC and the subsequent storage in 
secretory granules allow for an excellent discrimination of these tumors with 11C-5-HTP 
and 18F-DOPA as compared with normal tissue37. Due to low organ uptake of 11C-5-HTP, 
scans are characterized by a low background activity. 11C-5-HTP uptake by the kidneys and 
metabolization to serotonin by the AADC enzyme followed by subsequent urinary 
excretion, result in an intense signal in these organ systems. There is also some physiologic 
pancreatic uptake noticeable. This can lead to difficulties in the interpretation of lesions in 
the direct vicinity of these organs. However, the oral pre-medication with carbidopa lowers 
the metabolization to serotonin thereby reducing the signal intensity in this area, thus 
improving image quality and interpretability38. 
There are however two draw-backs for this tracer. The tracer synthesis is very complex 
since it relies on two complex multi-enzyme steps. Also the short half life of 20 min for 
11Carbon limits the use of this tracer to specialized centers with their own cyclotron 
cilities. Nevertheless, the published results with this tracer justify the use of this tracer. 
. Three different families of Na /Pi co-transporters have been reported, type I, 
 involved in the inorganic phosphate transport in cells. 





Inorganic phosphate (Pi) molecules and Na+ ions are taken up by cells via the Na+/Pi co-
transporters39 +
II and III. These transporters are
Type II and III are regula
II activity is decreased by acidic pH and increased with an alkaline pH. Type III functions 
in the opposite way, i.e. acidic pH increases its activity. The physiologic function of the 
Na+/Pi transporters is still not entirely clear. These transporters are predominantly 
expressed in kidney, liver and brain. The three families of this transporter ar






The uptake mechanism for Tc-(V)-DMSA is based on the resemblance between the 
TcO43- complex in labeled DMSA and the phosphate molecule PO43- 40. Due to the over 
expression of type III Na+/Pi transporters, lack of Type II Na+/Pi transporters and a more 
acidic extra cellular pH in tumor cells than normal tissue, tumor cells have a higher 
phosphate uptake. As 99mTc (V)-DMSA resembles the phosphate molecule, it is also 
actively taken up. 99mTc-(V)-DMSA is therefore a marker for the phosphate metabolism41. 
This tracer has thus far mainly been used for imaging medullary thyroid tumors. For the 
detection of this tumor type, 99mTc-(V)-DMSA is the routinely used tracer with the best 
results (figure 3). It has an average sensitivity of 76 % for medullary thyroid tumors (figure 
9). In these tumors, morphological imaging (CT/MRI) performs equally (sensitivity ranging 
from 67% to 87%)42,43. 
 
 
Figure 9. Forest plot analysis of 99mTc-(V)-DMSA imaging for medullary thyroid tumors. Results of DMSA imaging for medullary 
thyroid carcinoma in a Forest plot analysis. On the left side of this plot the tumor type is given with the tracers used in the 
presented studies. On the right side sensitivities from literature data are given with their calculated confidence interval. The size of 
the solid black square represents the weight the corresponding study exerts in this analysis and is calculated using the number of 
patients included (Mantel-Haenszel weight). 
 
Glucose metabolism 
Cells rely mostly on their glucose metabolism to obtain ATP as their energy source. After 
uptake by glucose transporters, glucose is phosphorylated by the hexokinase enzyme to a 
phosphorylated intermediate, which is eventually metabolized to pyruvate and lactate. This 
step does not require oxygen (anaerobic glycolysis). The next step, the citric acid cycle, 
requires oxygen (aerobic) and produces most of the ATP molecules. In the citric cycle, 
pyruvate is eventually metabolized to CO2. Tumor cells rely mainly on the anaerobic 
glycolysis with its relatively low energy yield, and therefore require much more glucose. 
0 20 40 60 80 100 
99Tc-(V)-DMSA 104 95% (84, 100) 
99Tc-(V)-DMSA 74 50% (27, 73) 
99Tc-(V)-DMSA 43 33% (21, 45) 
99Tc-(V)-DMSA 42 57% (41, 71) 
99Tc-(V)-DMSA 72 30% (17, 43) 
99Tc-(V)-DMSA 71 69% (55, 80) 
99Tc-(V)-DMSA 103 82% (49, 96) 
Sensitivity (%) 
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18F-Fluor-2-deoxy-D-Glucose PET 
18F-2-deoxy-D-glucose (FDG) is transported into the cells and then phosphorylated by 
hexokinase. This results in a polar intermediate (FDG-6p), which crosses the cell 
not have a high glycolysis rate. Results of FDG 
aging in neuroendocrine tumors are inferior to these obtained for metabolically active 
rine tumors which have a high uptake, such as small cell lung cancer, 
cids cells rely on the plasma 
embrane bound system L transporters. This system consists of two heterodimers 
able light chain, thus forming the LAT 1 to 
rt 
apabilities of neuroendocrine tumor cells. A study in 22 carcinoid patients showed an 
of 43% with a lower lesion contrast and image quality than 111In-
membrane poorly. The increased expression of the glucose transporter molecules and the 
hexokinase enzyme result in an increased uptake and retention of FDG in tumor cells 
compared to normal cells44. In general, FDG uptake increases when tumors behave more 
aggressively45. 
However, neuroendocrine tumors do 
im
tumors. Neuroendoc
are characterized by a more aggressive behavior46. The use of the FDG PET scan in 
neuroendocrine tumors is therefore more or less limited to imaging small cell lung cancer 
(with approximately 93% sensitivity) and medullary thyroid carcinoma (76% sensitivity). 
 
Large amino acid transport system 
To import large branched and aromatic neutral amino a
m
composed of a large glycoprotein part and a vari
5. System L transporters, which are amino acid transporters, are obligatory exchange 
transporters which can only function by exchanging an intracellular amino acid for an 
extra-cellular one. In combination with other unidirectional transporters with overlapping 
amino acid sensitivities, cells can control the activity of the system L transport. Over 
expression of amino acid transporters helps to satisfy the metabolic needs, but tumor cells 
can consume more nutrients than required for the metabolic needs. In neuroendocrine 
tumors the LAT2 transporters play an important role, due to their ability to take up large 
neutral amino acids such as phenylalanine and tryptophan. Thus far only L-3-123I-alpha-
methyl-tyrosine (123I-IMT) has been developed to exploit the over expression of the LAT 
system for imaging purposes in neuroendocrine tumors46,47. 
 
L-3-123I-alpha-methyl-tyrosine (123I-IMT) 
123I-IMT, an artificial amino acid derived from tyrosine, was initially developed as a 
functional imaging agent for neutral amino acid transport in brain tumors. 123I-IMT 
accumulates fast in neuroendocrine tumor cells due to uptake via LAT1, but is not further 
metabolized intra-cellularly48. Therefore, it can be regarded as a true marker for transpo
c
overall lesion detection 
octreotide49. 123I-IMT is not generally available. 
 
Radiolabeled monoclonal antibodies 
Only a few reports of patient studies with radio labeled monoclonal antibodies against 
antigens expressed on neuroendocrine tumors used for nuclear medicine imaging are 
available. Described applications are anti-CEA for paragangliomas, anti CgA for medullary 
thyroid carcinoma and anti- UJ13A and anti GD2 for neuroblastoma49-52. These reports 
should be seen as experimental, due to the limited data available and the fact that these 




123I and 131I-MIBG 63% (54, 72) 
11C-5-HTP 95% (78, 99) 
18F-DOPA 89% (81, 94,) 
123I-VIP 70% (65, 76) 
99mTc EDDA 90% (85, 94) 
111In-DOTA-TOC 87% (72, 96) 
 
T 
imaging. For SRS, different somatostatin analogues are investigated which are more stable 
and bind more receptor subtypes with a higher affinity. 
Most neuroendocrine tumors share common metabolic pathways, such as the catecholamine 
Figure 10. Summary of results. Results of all described imaging methods sorted per tumor type in a Forest plot analysis. On the left 
side of this plot the tumor type is given with the tracers used in the presented studies. On the right side sensitivities from literature 
data are given with their calculated confidence interval. The size of the solid black square represents the weight the corresponding 
study exerts in this analysis and is calculated using the number of patients included (Mantel-Haenszel weight). 
 
Conclusion 
Most receptor-based tracers have been developed for scintigraphic use, and changing to 
positron emitting labels (i.e. 18F, 64Cu, 68Ga) could make these tracers suitable for PE
0 20 40 60 80 100
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18FDG 79% (70, 86) 
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111In-Octreotide 49% (42, 57) 
111In-Octreotide 78% (51, 92) 
18FDG 72% (53, 87) 
123I and 131I-MIBG 79% (68, 82) 
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18F-DOPA 100% (76, 100) 
111In-Octreotide 63% (51, 73) 
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111In-Octreotide 74% (63, 83) 
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and serotonin pathways. Different strategies in the development of tracers suitable to 
odies specific for neuroendocrine tumors has thus far not been as successful 
d 
natomic images give surgeons essential information to guide surgical decision-making. 
d knowledge has been gathered in the past years with 
 analysis. 
m
o id) tumours and related lesions. World J 
-S114. 
visualize the metabolic pathways are possible. For example, three different tracers for the 
catecholamine pathway have been developed: the tracer 18FM-6-FmT is an aromatic L-
AADC inhibitor, 18F-DOPA is a substrate in the catecholamine synthesis, 18F-dopamine is 
stored in vesicles where it is metabolized to 18F-norepinephrin and 18F-epinephrin. Several 
other tracers, which exploit the metabolic characteristics, are in development.  
The use of antib
as the receptor and metabolic based imaging methods. It has been troubled by the high 
background uptake. 
The developments in the area of image fusion are also of great interest for neuroendocrine 
tumors. Nuclear medicine techniques lack anatomical information, whereas morphological 
imaging lacks functional information. Co-registration of these modalities, either by 
software or by hardware, assists in tumor localization. The combined functional an
a
An enormous amount of expertise an
somatostatin analogues, both for diagnostic and treatment purposes. It is more or less clear 
which tumor types can be visualized to what extend with this tracer. It can be expected that 
combining somatostatin analogues with positron emitting labels will secure its position 
within both diagnostic and therapeutic procedures in nuclear medicine in the near future. 
However, somatostatin receptors are not expressed evenly both in receptor subtypes and 
quantity of expressed receptors on the cellular membrane. Therefore other techniques will 
improve diagnostic imaging. Due to their common capability for the uptake of large amino 
acids for the incorporation in metabolic pathways, precursors (i.e. 18F-DOPA and 11C-5-
HTP) for these pathways are interesting candidates for diagnostic and therapeutic purposes.  
Although results are promising, experience with these PET tracers is still limited. It is 
foreseeable that in the future the first step in neuroendocrine tumor imaging will be with the 
use of PET tracers, such as 18F-DOPA on a PET-CT machine. When this combination 
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